CBER "COMPLETE REVIEW" LETTERS COULD REPLACE "APPROVABLE/NOT APPROVABLE"; INDUSTRY, FDA LIKELY TO ADDRESS "APPROVABLE" DECISIONS IN PDUFA REAUTHORIZATION
Executive Summary
FDA's Center for Biologics Evaluation & Research is using "complete review" letters to replace "approvable" or "not approvable" letters for non-user fee applications.
You may also be interested in...
“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials